Cerenome Inc (CNSY) Stock Price, Quote & News

Company Profile

Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various sol...

Industry: Biotechnology

Sector: Healthcare

Phone: 210 974 6900

Fax: 210 974 6901

Website: cerenome.com

Address:

6420 Levit Green Blvd, Suite 210, Houston, United States

ValuePrince Sep. 13 at 11:58 AM

$CNSY 🐋

0 · Reply

MrWicks Sep. 11 at 9:56 PM

$CNSY Reminds me of snakes and ladders this thing.

0 · Reply

Marketmoverjoe Sep. 11 at 8:37 PM

$CNSY Criminal company. they don't produce a thing. These CEO's should be looking over their shoulder. Flat out robbing folks with their BS. Never buy the news with this company. Do your DD. You'll conclude they have done nothing but rob people

0 · Reply

Vulnerable Sep. 11 at 8:21 PM

$CNSY who as the screen shot of Mo saying those waiting to my at all time lows were LOL and these #'s would never been seen again? A statement like that is about a reliable as Trump promising a dividend check. THANK YOU FOR YOUR ATTNTION TO THIS MATTER #shortmissiontocontinue

0 · Reply

Vulnerable Sep. 11 at 8:04 PM

$CNSY Shorts thank you Mo. Too much to ask when .33 happens? or is it .23? or when the next r/s is? Even w/o Mo posting, you can see the control. Clues like OG's posting they are buying is another correlation to the stock price going down. They (mo/OG's) always speak as higher is a rise in stock price but if you know they are shorts and can translate that 'higher' is acutally lower lows, then you have figured out the game and on your way to making bank. I think it was mackie who had a recent post about some of Mo's all time hits over the last 10 yrs. There would be more but they went out of business. Truly something special to keep these along and siphoning money for this long. Impressive MO.

1 · Reply

Kcmule Sep. 11 at 7:45 PM

$CNSY Finishing out the week by hitting fresh all time lows. Nice work @cerenome

0 · Reply

TALENT_ON_LOAN_FROM_GOD Sep. 11 at 5:30 PM

$BDRX $CNSY $NUWE GENIUS 🤡🤡🤡

0 · Reply

andre82 Sep. 11 at 5:24 PM

$CNSY 💰 Shorts laughing to the bank.

0 · Reply

andre82 Sep. 11 at 5:23 PM

$CNSY No whining, you can always make money in a scam! Just need to be on the right side. Sub 2 is coming very soon. Have a great weekend!

0 · Reply

fede1992juventus Sep. 10 at 2:39 PM

$CNSY It’s a good deal; it really looks like a bridge loan ahead of a potential sale in late 2027 or 2028

2 · Reply

Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment

Aug 20, 2026, 7:30 AM EDT - 24 days ago

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Aug 14, 2026, 4:15 PM EDT - 4 weeks ago

Cerenome Reports Second Quarter 2026 Financial Results and Business Update

Aug 14, 2026, 7:00 AM EDT - 4 weeks ago

Cerenome Quarterly report: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 4 weeks ago

Cerenome Earnings release: Q2 2026

Aug 13, 2026, 7:30 AM EDT - 4 weeks ago

Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives

Jul 31, 2026, 8:30 AM EDT - 6 weeks ago

Cerenome Launches as an Integrated CNS Oncology Company

Jul 28, 2026, 7:30 AM EDT - 6 weeks ago

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

Jul 21, 2026, 7:30 AM EDT - 7 weeks ago

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Jul 16, 2026, 7:30 AM EDT - 1 month ago

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

Jul 14, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

Jun 30, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding

Jun 25, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Jun 23, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics to Provide Business Update Call on June 30, 2026

Jun 4, 2026, 7:30 AM EDT - 3 months ago

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

May 26, 2026, 7:30 AM EDT - 3 months ago

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

May 19, 2026, 7:30 AM EDT - 3 months ago

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

May 15, 2026, 4:05 PM EDT - 4 months ago

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

May 8, 2026, 7:30 AM EDT - 4 months ago

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

May 7, 2026, 7:30 AM EDT - 4 months ago

Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic

Apr 28, 2026, 7:30 AM EDT - 4 months ago

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Apr 23, 2026, 7:30 AM EDT - 4 months ago

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

Apr 22, 2026, 4:30 PM EDT - 4 months ago

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Apr 21, 2026, 7:30 AM EDT - 4 months ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 15, 2026, 7:30 AM EDT - 5 months ago

Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

Apr 9, 2026, 7:30 AM EDT - 5 months ago

Plus Therapeutics Appoints Eric J. Daniels, M.D.

Apr 8, 2026, 7:30 AM EDT - 5 months ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

Apr 7, 2026, 7:30 AM EDT - 5 months ago

Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

Apr 2, 2026, 7:30 AM EDT - 5 months ago

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

Mar 26, 2026, 7:30 AM EDT - 5 months ago

Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

Mar 19, 2026, 7:30 AM EDT - 5 months ago

Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

Mar 12, 2026, 4:15 PM EDT - 6 months ago

Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

Feb 25, 2026, 7:30 AM EST - 6 months ago

Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

Jan 21, 2026, 4:15 PM EST - 7 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

Jan 14, 2026, 8:00 AM EST - 8 months ago

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

Jan 8, 2026, 7:30 AM EST - 8 months ago

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

Dec 11, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Expands CNSide Assay Platform to State of California

Dec 9, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

Dec 4, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Dec 1, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Nov 24, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Nov 20, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Nov 17, 2025, 7:30 AM EST - 10 months ago

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Nov 6, 2025, 7:30 AM EST - 10 months ago

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Oct 30, 2025, 4:15 PM EDT - 10 months ago

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Oct 21, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Sep 25, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Sep 22, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Sep 18, 2025, 7:30 AM EDT - 12 months ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Sep 2, 2025, 4:15 PM EDT - 1 year ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 18, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

ValuePrince Sep. 13 at 11:58 AM

$CNSY 🐋

0 · Reply

MrWicks Sep. 11 at 9:56 PM

$CNSY Reminds me of snakes and ladders this thing.

0 · Reply

Marketmoverjoe Sep. 11 at 8:37 PM

0 · Reply

Vulnerable Sep. 11 at 8:21 PM

0 · Reply

Vulnerable Sep. 11 at 8:04 PM

1 · Reply

Kcmule Sep. 11 at 7:45 PM

$CNSY Finishing out the week by hitting fresh all time lows. Nice work @cerenome

0 · Reply

TALENT_ON_LOAN_FROM_GOD Sep. 11 at 5:30 PM

$BDRX $CNSY $NUWE GENIUS 🤡🤡🤡

0 · Reply

andre82 Sep. 11 at 5:24 PM

$CNSY 💰 Shorts laughing to the bank.

0 · Reply

andre82 Sep. 11 at 5:23 PM

$CNSY No whining, you can always make money in a scam! Just need to be on the right side. Sub 2 is coming very soon. Have a great weekend!

0 · Reply

fede1992juventus Sep. 10 at 2:39 PM

$CNSY It’s a good deal; it really looks like a bridge loan ahead of a potential sale in late 2027 or 2028

2 · Reply

andre82 Sep. 10 at 2:27 PM

$CNSY quick 8k review reveals this is still hot garbage. Even if we put perfume on top. 😁

1 · Reply

MarkeTimer Sep. 10 at 2:12 PM

$CNSY To collateralize to loan (for royalty payback), a future CNSide revenue model was presented - what the hell is it?

0 · Reply

cerenome Sep. 10 at 12:20 PM

$CNSY announces that it has entered into a financing agreement with 3i, LP (3i Fund) for a senior secured facility of up to $20 million with royalty-based repayments. Under the agreement, $CNSY received initial funding at closing, with future tranches available upon achieving certain milestones. The financing is intended to support the scale-up of the Company’s proprietary laboratory-developed tests, particularly its CNSide Diagnostics’ cerebrospinal fluid assay platform. Read more: https://ir.cerenome.com/news-releases/news-release-details/cerenome-announces-20-million-financing-facility-royalty-based/?utm_source=social

1 · Reply

Igotgame1 Sep. 10 at 12:05 PM

$CNSY [..]We forecast our cash runway is now well into 2028 when we consider, the 3i facility, other existing facilities along with current cash and forecasted CNSide related sales and cash flow[..] Turnaround

0 · Reply

MarkeTimer Sep. 10 at 11:17 AM

$CNSY Beneficial financing news.

1 · Reply

andre82 Sep. 10 at 1:04 AM

$CNSY $BDRX $NUWE One of the short side indicator profiles. Dump it baby! Daddy is ready to cash out. 💰🤑

3 · Reply

TheRipple Sep. 9 at 11:37 PM

$CNSY $BDRX $NUWE Throttle me baby.

0 · Reply

Mackie2020 Sep. 9 at 9:13 PM

$CNSY $NUWE $BDRX Top 20 worst performing healthcare stocks the past 10 years - Updated

4 · Reply

billsmall Sep. 9 at 9:06 PM

$CNSY It's OK Mo says something about a wormhole and his beloved. He must have fell into that wormhole. LAMO

0 · Reply

Lehameri Sep. 9 at 3:45 PM

$CNSY not dismissing the achievements of the company thus far and the benefits for it will have for many. Its awesome. A move to fill the gap up their would be more of a psychological relief because of the many years of shorting rather than something substantial (as it would only be around .60's presplit). Stocks have made major moves on lesser news. It is now .10 pre split. Not trying to complain nor trying to be entitled. im just tired of saying its been difficult and frustrating.

1 · Reply

Lehameri Sep. 9 at 3:15 PM

$CNSY lets just say it goes to double digits from God knows how low. Some folks will jump in start immediately talking about buyout and how they have all the information in the world on the company. While longs are still down the majorly. Fine life isnt fair but why the constant need for it to keep going down? Its so frustrating all they have done is down over the years even when they are up; still down.

1 · Reply

andre82 Sep. 9 at 3:07 PM

$CNSY Lets gooo. 1.xx coming up in days/weeks not months.

0 · Reply

Market Cap	17.65M
Revenue (ttm)	5.21M
Net Income (ttm)	-22.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-429.75%
Debt to Equity Ratio	0.00

Volume	79,900
Avg Vol	95,506
Day's Range	N/A - N/A
Shares Out	7.59M
Stochastic %K	2%
Beta	1.39
Analysts	Strong Sell
Price Target	$27.50